Natural Capsules cash flow

Latest FY26
Cash from operations
₹10.9cr−59.2% on FY25
Capital spending
₹11.5cr−74.2% on FY25
Free cash flow
−₹0.6cr−₹17.9 cr in FY25
Cash from financing
−₹0.6cr₹16.2 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—17.19.1
—10.96.3
—2.20.3
—0.60.8
—−0.0−0.4
Changes in working capital
—−0.9−6.4
—−9.7−8.5
—−0.6−0.0
—2.30.3
—0.00.1
—−0.06.5
—16.88.1
—−0.87.5
—4.01.8
—0.5−0.5
—0.71.4
Cash from operating activities
−27.7−27.92.8
—43.226.2
—15.329.0
—−0.8−0.1
—3.62.1
—10.926.8
Cash from investing activities
—11.544.6
—0.80.1
—−10.8−44.5
Cash from financing activities
—0.027.8
—10.50.0
—0.05.2
—0.40.2
—10.86.3
—−0.616.2
—−0.5−1.6
—−0.5−1.6
Reference items
−0.8−1.617.5
−0.4%−0.8%10.4%
−0.6−0.6−17.9
—−0.9—
−₹0.59−₹0.59−₹17.21
—−0.44×43.33×
—3.62.1
—10.86.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCAPSUQ₹136.44

Natural Capsules Limited

· Pharma & Health
₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLABMcap ₹142 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation9.117.1—
+ Finance Costs6.310.9—
+ Share-based Payments0.32.2—
+ Other Non-cash Items0.80.6—
+ Other Reconciling Items-0.4-0.0—
Changes in Working Capital
+ Inventories-6.4-0.9—
+ Trade Receivables — Current-8.5-9.7—
+ Other Financial Assets — Non-current-0.0-0.6—
+ Other Current Assets0.32.3—
+ Other Non-current Assets0.10.0—
+ Other Bank Balances6.5-0.0—
+ Trade Payables — Current8.116.8—
+ Other Financial Liabilities — Current7.5-0.8—
+ Other Current Liabilities1.84.0—
+ Provisions — Current-0.50.5—
+ Provisions — Non-current1.40.7—
Cash from Operating Activities
Profit Before Tax (per I/S)2.8-27.9-27.7
+ Total Adjustments (incl. Working Capital)26.243.2—
Cash from Operations (pre-tax)29.015.3—
+ Interest Received — Operating-0.1-0.8—
+ Income Taxes Paid2.13.6—
Cash from Operating Activities26.810.9—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)44.611.5—
+ Interest Received — Investing0.10.8—
Cash from Investing Activities-44.5-10.8—
Cash from Financing Activities
+ Proceeds from Issue of Shares27.80.0—
+ Proceeds from Borrowings0.010.5—
+ Repayment of Borrowings5.20.0—
+ Payment of Lease Liabilities0.20.4—
+ Interest Paid6.310.8—
Cash from Financing Activities16.2-0.6—
Net Changes in Cash (pre-FX)-1.6-0.5—
Net Changes in Cash-1.6-0.5—
Reference Items
EBITDA17.5-1.6-0.8
EBITDA Margin %10.35-0.83-0.40
Free Cash Flow (CFO − Capex)-17.9-0.6-0.6
Free Cash Flow to Equity—-0.9—
Free Cash Flow per Basic Share-17.21-0.59-0.59
Cash Flow to Net Income43.33-0.44—
Cash Paid for Taxes2.13.6—
Cash Paid for Interest6.310.8—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.